表紙SALE
市場調查報告書
商品編碼
1027921

核醫學市場預測/競爭趨勢/增長機會(~2026):類型(診斷/治療)/使用(診斷/治療)/最終用戶/地區

Global Nuclear Medicine Market By Type, By Diagnostic Nuclear Medicine, By Therapeutic Nuclear Medicine, By Application, By Diagnostic Applications, By Therapeutic Applications, By End User, By Region, Competition, Forecast & Opportunities, 2026

出版日期: | 出版商: TechSci Research | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

  • 全貌
  • 簡介
  • 目錄
簡介

全球核醫學市場正在增加癌症等疾病的發病率和患病率,努力縮小Mo-99供需缺口,以及對各種疾病的輻射。預計將顯示顯著預測期內的增長,包括由於治療研發的增加。

核醫學也廣泛用於分子成像。

本報告探索全球核醫學市場,定義和概述市場,分析新型冠狀病毒感染(COVID-19)和其他市場影響因素,分析客戶反饋和市場規模。趨勢/預測,按類型細分/用途/最終用戶、按地區/主要國家、競爭環境、市場份額、主要公司簡介等進行詳細分析。

目錄

第 1 章產品概述

第二章調查方法

第 3 章 COVID-19 的影響

第 4 章執行摘要

第五章客戶反饋

第 6 章世界市場展望

  • 市場規模/預測
  • 市場份額/預測
    • 按類型
      • 用於診斷
      • 用於治療
      • 近距離放射治療同位素
    • 按應用程序
      • 診斷
      • 治療
    • 最終用戶
      • 醫院/診所
      • 診斷中心
      • 學術/研究機構
    • 按公司
    • 按地區
  • 產品市場地圖

第七章亞太市場分析/預測

  • 市場規模/預測
  • 市場份額/預測
    • 按類型
    • 按應用程序
    • 最終用戶
    • 按國家/地區

第八章歐洲市場分析與預測

  • 市場規模/預測
  • 市場份額/預測
    • 按類型
    • 按應用程序
    • 最終用戶
    • 按國家/地區

第九章北美市場分析與預測

  • 市場規模/預測
  • 市場份額/預測
    • 按類型
    • 按應用程序
    • 最終用戶
    • 按國家/地區

第10章南美市場分析/預測

  • 市場規模/預測
  • 市場份額/預測
    • 按類型
    • 按應用程序
    • 最終用戶
    • 按國家/地區

第11章中東和非洲市場分析與預測

  • 市場規模/預測
  • 市場份額/預測
    • 按類型
    • 按應用程序
    • 最終用戶
    • 按國家/地區

第 12 章市場動態

  • 促進因素
  • 挑戰

第 13 章市場趨勢

第14章競爭形勢

  • 競爭前景
  • 公司簡介
    • Cardinal Health, Inc.
    • GE Healthcare
    • Curium SAS
    • Lantheus Medical Imaging, Inc.
    • Bayer AG
    • Bracco Imaging S.p.A.
    • Nordion Inc.
    • Novartis AG(Advanced Accelerator Applications SA)
    • Isotopia Molecular Imaging Limited
    • NorthStar Medical Radioisotopes, LLC

第15章 策略建議

第16章 關於出版商&免責事項

目錄
Product Code: 4562

Global nuclear medicine market is estimated to grow at an impressive rate during the forecast period owing to increasing incidence and prevalence of diseases like cancer, initiatives to reduce the demand and supply gap of Mo-99 and increasing research and development activities in radiotherapy to treat various diseases. Furthermore, nuclear medicines are extensively being used in molecular imaging, which is a technique involving molecules as biomarkers for specific molecular processes that determines the onset or progress of a disease.

Nuclear medicines are convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Due to this major factor, chemotherapy methods are being replaced by radiopharmaceuticals or nuclear medicines for cancer treatment. They are also used in applications such as lymphoma and bone metastasis. Some of the nuclear medicines used in diagnostic procedures are F-18, Tc-99, Ga-67, and I-123 while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures. These factors are anticipated to drive global nuclear medicine market until 2026.

Apart from above mentioned growth factors, the global nuclear medicine market also faces some restrains. Short half-life of nuclear medicines or radiopharmaceuticals reduces their potential adoption. Other restraining factors include supply shortages, logistical difficulties, and limited number of trained medical personnel.

The global nuclear medicine market is segmented based on therapy, type, application, therapeutics, route of administration, end-user and region. Based on type, the nuclear medicine market is segmented into Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes. Diagnostic Nuclear Medicine can further be split into SPECT Radiopharmaceuticals and PET Radiopharmaceuticals. The SPECT Radiopharmaceuticals segment accounts for the largest market share and is expected to hold its dominance in the coming years owing to low cost and wide usage in different applications.

Major players operating in the global nuclear medicine market include Cardinal Health, Inc., GE Healthcare, Curium SAS, Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.p.A., Nordion Inc., Novartis AG (Advanced Accelerator Applications SA), Isotopia Molecular Imaging Limited, NorthStar Medical Radioisotopes, LLC and others. Key market players are implementing activities like product developments, business expansion, and collaborative development to maintain significant share in the market for nuclear medicine.

Years considered for this report:

  • Historical Years: 2016-2019
  • Base Year: 2020
  • Estimated Year: 2021
  • Forecast Period: 2022-2026

Objective of the Study:

  • To analyze and forecast the market size of global nuclear medicine market.
  • To classify and forecast global nuclear medicine market based on therapy, type, application, therapeutics, route of administration, end-user, company and regional distribution.
  • To identify drivers and challenges for global nuclear medicine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global nuclear medicine market.
  • To conduct pricing analysis for global nuclear medicine market.
  • To identify and analyze the profile of leading players operating in global nuclear medicine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global nuclear medicine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Nuclear medicine manufacturer, suppliers, distributors and other stakeholders
  • Hospitals & Clinics
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to nuclear medicine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global nuclear medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Nuclear Medicine Market, By Type:

  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • PET Radiopharmaceuticals
  • Therapeutic Nuclear Medicine
    • Alpha Emitters
    • Beta Emitters
  • Brachytherapy Isotopes

Global Nuclear Medicine Market, By Application:

  • Diagnostic Applications
    • SPECT Applications
    • PET Applications
  • Therapeutic Applications
    • Thyroid Indications
    • Bone Metastasis
    • Lymphoma
    • Endocrine Tumors
    • Others
    • Global Nuclear Medicine Market, By End User:
  • Hospitals & Clinics
  • Diagnostic Centers
  • Academic & Research Institutions

Global Nuclear Medicine Market, By Region:

  • Asia-Pacific
  • Europe
  • North America
  • South America
  • Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nuclear medicine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Nuclear Medicine Market

4. Executive Summary

5. Voice of Customer

6. Global Nuclear Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
      • 6.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
      • 6.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
    • 6.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
      • 6.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
      • 6.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
    • 6.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
    • 6.2.4. By Company (2020)
    • 6.2.5. By Region
  • 6.3. Product Market Map

7. Asia-Pacific Nuclear Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
      • 7.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
      • 7.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
    • 7.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
      • 7.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
      • 7.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
    • 7.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
    • 7.2.4. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Nuclear Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. India Nuclear Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Japan Nuclear Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. South Korea Nuclear Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Australia Nuclear Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Europe Nuclear Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
      • 8.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
      • 8.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
    • 8.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
      • 8.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
      • 8.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
    • 8.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Nuclear Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Nuclear Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Nuclear Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Nuclear Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Nuclear Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. North America Nuclear Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
      • 9.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
      • 9.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
    • 9.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
      • 9.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
      • 9.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
    • 9.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Nuclear Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Mexico Nuclear Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Canada Nuclear Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Nuclear Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
      • 10.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
      • 10.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
    • 10.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
      • 10.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
      • 10.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
    • 10.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Nuclear Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Nuclear Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Nuclear Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Middle East and Africa Nuclear Medicine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes)
      • 11.2.1.1. By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals)
      • 11.2.1.2. By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters)
    • 11.2.2. By Application (Diagnostic Applications v/s Therapeutic Applications)
      • 11.2.2.1. By Diagnostic Applications (SPECT Applications v/s PET Applications)
      • 11.2.2.2. By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others)
    • 11.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Nuclear Medicine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Application
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Nuclear Medicine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Application
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Nuclear Medicine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Application
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Company Profiles (SWOT Analysis of Top 5 Players Profiled)
    • 14.2.1. Cardinal Health, Inc.
    • 14.2.2. GE Healthcare
    • 14.2.3. Curium SAS
    • 14.2.4. Lantheus Medical Imaging, Inc.
    • 14.2.5. Bayer AG
    • 14.2.6. Bracco Imaging S.p.A.
    • 14.2.7. Nordion Inc.
    • 14.2.8. Novartis AG (Advanced Accelerator Applications SA)
    • 14.2.9. Isotopia Molecular Imaging Limited
    • 14.2.10. NorthStar Medical Radioisotopes, LLC

15. Strategic Recommendations

16. About Us & Disclaimer

(Note: The companies list can be customized based on the client requirements)